1. Long-term effects of melatonin and resveratrol on aging rats: A multi-biomarker approach.
- Author
-
Breljak D, Micek V, Gerić M, Gajski G, Oguić SK, Rašić D, Karaica D, Madunić IV, Ljubojević M, Orct T, Jurasović J, Jovanović IN, Peraica M, Nanić L, Rubelj I, and Sabolić I
- Subjects
- Aging, Animals, Biomarkers, Female, Glutathione, Male, Malondialdehyde, Rats, Rats, Wistar, Resveratrol pharmacology, Water, Melatonin pharmacology
- Abstract
Aging-related impaired body structure and functions may be, at least partially, caused by elevated oxidative stress. Melatonin (MEL) and resveratrol (RSV) may act as antioxidant and anti-aging compounds, but these actions in experimental animals and humans are controversial. Herein, a rat model of aging was used to study the long-term sex-related effects of MEL and RSV treatment on body mass and blood/plasma parameters of DNA damage, oxidative status (glutathione and malondialdehyde levels), and concentrations of sex hormones. Starting from the age of 3mo, for the next 9mo or 21mo male and female Wistar rats (n = 4-7 per group) were given water to drink (controls) or 0.1 % ethanol in water (vehicle), or MEL or RSV (each 10 mg/L vehicle). DNA damage in whole blood cells was tested by comet assay, whereas in plasma, glutathione, malondialdehyde, and sex hormones were determined by established methods. Using statistical analysis of data by ANOVA/Scheffe post hoc, we observed a similar sex- and aging-dependent rise of body mass in both sexes and drop of plasma testosterone in control and vehicle-treated male rats, whose pattern remained unaffected by MEL and RSV treatment. Compared with controls, all other parameters remained largely unchanged in aging and differently treated male and female rats. We concluded that the sex- and aging-related pattern of growth and various blood parameters in rats were not affected by the long-term treatment with MEL and RSV at the estimated daily doses (300-400 μg/kg b.m.) that exceed usual moderate consumption in humans., (Copyright © 2022 Elsevier B.V. All rights reserved.)
- Published
- 2022
- Full Text
- View/download PDF